Document is current

Any future updates will be listed below

Comment on “SMPDL3B as a novel biomarker and therapeutic target in myalgic encephalomyelitis” critical considerations on biomarker validation and Supraphysiological drug concentrations

Crossref DOI link: https://doi.org/10.1186/s12967-025-07121-x

Published Online: 2025-11-20

Update policy: https://doi.org/10.1007/springer_crossmark_policy

About CrossMark